Kymera Therapeutics, Inc. Common Stock KYMR

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

• The Motley Fool 12 jul

  Kymera's CEO Sold $6 Million in Stock After a 170% Run

  Kymera Therapeutics CEO Nello Mainolfi sold 50,000 shares for $6 million on July 7, 2026, following a 170% stock surge over 12 months. The sale involved exercising options at $2.08 and selling at $119 per share under a pre-scheduled Rule 10b5-1 trading plan. Despite the sale, Mainolfi retains 666,568 shares worth $79.5 million and 90,000 options, indicating continued confidence in the company's pipeline, particularly KT-621 in Phase 2b trials with FDA Fast Track status.

  

• GlobeNewswire Inc. 12 jun

  Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

  Kymera Therapeutics announced Phase 1 results for KT-621, a first-in-class oral STAT6 degrader, in healthy Japanese adults at the Japanese Dermatological Association Annual Meeting. The data showed consistent safety and pharmacokinetic/pharmacodynamic profiles with previous studies, demonstrating rapid and sustained STAT6 degradation (≥98% at Day 7). The company has parallel Phase 2b trials ongoing in atopic dermatitis (BROADEN2) and asthma (BREADTH), with data expected by mid-2027 and late 2027, respectively.